Margolese, M.D., C.M., Paul T. Adams, M.D., Howard M. Gross, M.D., Joseph P. Costantino, Dr.P.H., Sandra M. Swain, M.D., Eleftherios P. Mamounas, M.D., and Norman Wolmark, M.D.: Bevacizumab Added to Neoadjuvant Chemotherapy for Breasts Cancer Neoadjuvant chemotherapy is becoming established as an acceptable option to adjuvant chemotherapy for operable breast cancer, because it can increase the rates of breast-conserving surgery1-3 and reduce the need for complete axillary lymph-node dissection.4-6 Neoadjuvant chemotherapy offers the prospect of rapidly assessment regimens that might improve response rates and for that reason may be likely to enhance the outcomes in individuals. Although alterations in neoadjuvant chemotherapy that increase the rates of pathological full response might not necessarily improve survival,5,7 the outcomes of the National Surgical Adjuvant Breasts and Bowel Task B-27 trial of neoadjuvant therapy were concordant with those of randomized trials of adjuvant therapy that showed improved outcomes with the help of taxanes.3,8-11 Evaluation of responses of tumors to neoadjuvant therapy in individuals who have not previously been exposed to systemic therapies is actually a more useful strategy for determining the drugs or regimens that are value testing in trials of adjuvant therapy than a technique of using results from studies involving individuals with metastatic disease.Charles A. Sanders, Chairman of the Table, Foundation for NIH.S. KEYNOTE Loudspeakers Keynote addresses will be delivered by senior officials including: Kathleen Sebelius, Secretary of Health insurance and Human Providers ; Dr. Francis S. Collins, newly appointed Director of the National Institutes of Health ; Dr. Ileana Arias, Acting Principal Deputy Director of the Centers for Disease Control and Prevention ; Ambassador Elizabeth Frawley Bagley, Special Representative for Global Partnerships, U.S. Department of State; Ambassador Eric Goosby, U.S. Roberto Tapia-Conyer, Director General of the Carso Health Institute of Mexico. THE CONFERENCE PROGRAM Opening time discussions include a panel moderated by Dr.